Source comparison
Receptor Mechanisms: Direct Activation vs Secretagogue Pathway
IGF-1 LR3 binds directly to IGF-1 receptors on muscle, bone, and connective tissue with approximately 80% of the affinity of native IGF-1. The 13-amino-acid N-terminal extension and glutamic acid substitution at position 3 reduce binding to IGFBPs by more than
This comparison does not assign a generated winner or score.
- IGF-1 LR3 binds directly to IGF-1 receptors on muscle, bone, and connective tissue with approximately 80% of the affinity of native IGF-1. The 13-amino-acid N-terminal extension and glutamic acid substitution at position 3 reduce binding to IGFBPs by more than 90%, which normally sequester IGF-1 in circulation and prevent receptor activation. The result: more unbound IGF-1 LR3 molecules reach target tissues, and each molecule remains bioavailable for 20–30 hours instead of the 10–12 hours typical of endogenous IGF-1.
- MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist. It binds the growth hormone secretagogue receptor (GHS-R1a) in the anterior pituitary and arcuate nucleus of the hypothalamus, triggering endogenous growth hormone release. Growth hormone then travels to the liver, stimulating hepatic IGF-1 synthesis and secretion. This pathway preserves physiological pulsatility—GH levels rise in predictable waves, not sustained elevation—which means IGF-1 increases are moderate and subject-dependent. A 1998 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that MK-677 at 25mg daily increased mean serum IGF-1 by 60–90 ng/mL in healthy young adults, but peak levels remained within 2 standard deviations of baseline in 40% of subjects.
- The pharmacological difference: IGF-1 LR3 bypasses the entire GH→liver→IGF-1 axis. MK-677 depends on it. In research models with impaired GH secretion or hepatic dysfunction, MK-677's efficacy drops significantly. IGF-1 LR3 remains effective regardless of endogenous hormone status because it is the receptor ligand itself.